Poly ICLC
Showing 26 - 50 of 439
Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma Trial in Buffalo (biological, drug, other)
Completed
- Fallopian Tube Carcinoma
- +2 more
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401
- +4 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jul 20, 2021
Follicular Lymphoma Trial in Saint Louis (biological, drug, procedure)
Suspended
- Follicular Lymphoma
- Personalized tumor vaccine
- +6 more
-
Saint Louis, MissouriWashington University School of Medicine
Nov 9, 2021
Lung Carcinoma Trial in Rochester, Pittsburgh (Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine)
Active, not recruiting
- Lung Carcinoma
- Laboratory Biomarker Analysis
- MUC1 Peptide-Poly-ICLC Vaccine
-
Rochester, Minnesota
- +1 more
Feb 24, 2022
Low Grade Glioma Trial in Pittsburgh (Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC)
Recruiting
- Low Grade Glioma
- Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC
-
Pittsburgh, PennsylvaniaChildren's Hospital of Pittsburgh of UPMC
Aug 3, 2021
Myelofibrosis, Essential Thrombocythemia, MPN Trial in New York (Peptide-based vaccine, Poly ICLC)
Not yet recruiting
- Myelofibrosis
- +2 more
- Peptide-based vaccine
- Poly ICLC
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Jun 7, 2022
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Active, not recruiting
- Platinum-Resistant Fallopian Tube Carcinoma
- +5 more
- Atezolizumab
- +4 more
-
Tucson, Arizona
- +16 more
Oct 19, 2022
Urothelial/Bladder Cancer, Nos Trial in New York (Atezolizumab, PGV001, Poly ICLC)
Completed
- Urothelial/Bladder Cancer, Nos
- Atezolizumab
- +3 more
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Mar 7, 2022
Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary Trial in United States (DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly
Completed
- Cutaneous Melanoma
- +11 more
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401
- +2 more
-
Chicago, Illinois
- +6 more
Nov 10, 2021
Pediatric Brain Tumor Trial (biological, drug, procedure)
Withdrawn
- Pediatric Brain Tumor
- Personalized peptide vaccine
- +2 more
- (no location specified)
May 21, 2021
Glioblastoma Trial in Saint Louis (NeoVax, Nivolumab, Ipilimumab)
Terminated
- Glioblastoma
- NeoVax
- +4 more
-
Saint Louis, MissouriWashington University School of Medicine
Oct 26, 2021
Fibrolamellar Hepatocellular Carcinoma (FLC) Trial in Baltimore (DNAJB1-PRKACA peptide vaccine, Nivolumab, Ipilimumab)
Recruiting
- Fibrolamellar Hepatocellular Carcinoma (FLC)
- DNAJB1-PRKACA peptide vaccine
- +2 more
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center
Mar 3, 2022
Allergic Rhinitis, Asthma, Latent Tuberculosis Trial in Paddington (Poly ICLC, Poly I:C, R848)
Completed
- Allergic Rhinitis
- +2 more
- Poly ICLC
- +5 more
-
Paddington, London, United KingdomImperial Clinical Respiratory Research Unit (ICRRU), St Mary's H
Nov 3, 2021
Solid Cancer Trial in Chevy Chase, Easton, New York (Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or
Terminated
- Solid Cancer
- Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months
-
Chevy Chase, Maryland
- +2 more
Jan 27, 2021
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma Trial in United
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +2 more
- Carboplatin
- +6 more
-
Orange, California
- +15 more
Aug 23, 2022
Low-Grade B-cell Lymphoma Trial in New York (rhuFlt3L/CDX-301, Poly-ICLC)
Recruiting
- Low-Grade B-cell Lymphoma
- rhuFlt3L/CDX-301
- Poly-ICLC
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Nov 17, 2020
Metastatic Castration-resistant Prostate Cancer Trial in United States (drug, radiation, device)
Completed
- Metastatic Castration-resistant Prostate Cancer
- NKTR-214 (Cohort A)
- +6 more
-
Los Angeles, California
- +5 more
Nov 10, 2022
Prostate Cancer Trial in New York (PGV-001, Poly-ICLC, CDX-301)
Recruiting
- Prostate Cancer
- PGV-001
- +2 more
-
New York, New YorkIcahn School of Medicine at Mount Sinai (ISMMS)
Aug 10, 2021
Solid Tumors Trial in New York (Peptides, Poly-ICLC, Lenalidomide)
Completed
- Solid Tumors
- Peptides
- +2 more
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Jan 7, 2021
Head and Neck Carcinoma, Adult Disease Trial in Villejuif (HPVDC injection level dose 1, injection level dose 1, HPVDC
Recruiting
- Head and Neck Carcinoma
- Adult Disease
- HPVDC injection level dose 1
- +3 more
-
Villejuif, FranceGustave Roussy
Aug 17, 2023
Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma Trial in United States (Durvalumab, Tremelimumab, Poly ICLC)
Completed
- Head and Neck Squamous Cell Carcinoma
- +10 more
- Durvalumab
- +2 more
-
Atlanta, Georgia
- +6 more
Mar 1, 2022
Melanoma, Head Neck Cancer, Sarcoma Trial in United States (Hiltonol)
Completed
- Melanoma
- +3 more
- Hiltonol
-
Chevy Chase, Maryland
- +4 more
Dec 15, 2020
Breast Cancer Trial in Charlottesville (poly-ICLC, 9 Peptides from Her-2/neu, CEA, & CTA, Peptide-tet)
Terminated
- Breast Cancer
- poly-ICLC
- +2 more
-
Charlottesville, VirginiaUniversity of Virginia Health System
May 7, 2020
Melanoma Trial in Boston (Poly-ICLC, Peptides)
Completed
- Melanoma
- Poly-ICLC
- Peptides
-
Boston, Massachusetts
- +1 more
Dec 7, 2020
Breast Cancer Trial in Tampa, Boston, New York (PVX-410, Durvalumab, Hiltonol)
Active, not recruiting
- Breast Cancer
- PVX-410
- +2 more
-
Tampa, Florida
- +4 more
May 7, 2021
Melanoma, Metastatic Melanoma Trial in Boston (CDX-301, NEOVAX, Nivolumab)
Recruiting
- Melanoma
- Metastatic Melanoma
- CDX-301
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 12, 2023